Q

    Q32 Bio Inc (QTTB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.87
    -0.16 (-1.06%)

    Market Cap: $447.44M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    41%(14/34)
    Avg Surprise
    -631.64%
    Streak
    7 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.33
    Range$-0.42 - $-0.27
    6 analysts
    EPS Revisions
    2
    0
    7d
    2
    1
    30d
    EPS Estimate Drift
    90d ago$-0.41-24.9%
    60d ago$-0.41-24.9%
    30d ago$-0.38-17.5%
    7d ago$-0.31+5.8%
    Current$-0.33
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    Dec 31, 2026
    EPS Consensus$0.42
    Range$0.42 - $0.42
    1 analysts
    Revenue Consensus
    $-200000
    Range$-600000 - $1M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.42---
    Sep 26EST
    		-$-0.33---
    Jun 26
    		$-0.44$-0.53+16.98%Beat+43.6%
    Mar 26
    		$-0.54$-0.68+20.59%Beat+40.0%
    Dec 25
    		$4.58$-0.86+632.56%Beat+494.8%
    Sep 25
    		$-0.60$-1.19+49.58%Beat+58.9%
    Jun 25
    		$-0.78$-0.98+20.41%Beat+45.1%
    Mar 25
    		$-0.90$-1.23+26.83%Beat-187.4%
    Dec 24
    		$-1.16$-1.53+24.18%Beat-314.3%
    Sep 24
    		$-1.46$-1.45-0.69%Miss-156.1%
    Jun 24
    		$-1.42$-1.04-36.54%Miss-132.8%
    Mar 24
    		$1.03$-1.41+173.05%Beat+306.0%
    Dec 23
    		$-0.28$-0.30+6.67%Beat+97.4%
    Sep 23
    		$-0.57$-0.43-32.56%Miss+94.6%
    Jun 23
    		$-0.61$-0.50-22.00%Miss+93.4%
    Mar 23
    		$-0.50$-0.52+3.85%Beat-101.7%
    Dec 22
    		$-10.80$-0.49-2094.23%Miss-1.7%
    Sep 22
    		$-10.62$-0.46-2226.91%Miss-9.3%
    Jun 22
    		$-9.18$-0.54-1607.59%Miss+5.6%
    Mar 22
    		$28.62$-0.49+5909.99%Beat+8050.0%
    Dec 21
    		$-10.62$-0.57-1748.89%Miss+4.8%
    Sep 21
    		$-9.72$-0.59-1555.88%Miss+12.9%
    Jun 21
    		$-9.72$-0.57-1590.43%Miss+30.8%
    Mar 21
    		$-0.36$-0.61+41.35%Beat+97.4%
    Dec 20
    		$-11.16$-0.66-1593.99%Miss-12.7%
    Sep 20
    		$-11.16$-0.81-1279.82%Miss+7.5%
    Jun 20
    		$-14.04$-0.74-1797.30%Miss-27.9%
    Mar 20
    		$-14.04$-0.69-1934.78%Miss-21.9%
    Dec 19
    		$-9.90$-0.68-1355.88%Miss-7.8%
    Sep 19
    		$-12.06$-0.60-1910.00%Miss-67.5%
    Jun 19
    		$-10.98$-0.55-1896.36%Miss-6762.5%
    Mar 19
    		$-11.52$-0.54-2033.33%Miss-7580.0%
    Dec 18
    		$-9.18$-0.44-1986.36%Miss-2768.7%
    Sep 18
    		$-7.20$-0.37-1845.95%Miss-
    Jun 18
    		$-0.16N/A+51.52%Beat-
    Mar 18
    		$-0.15N/A+96.03%Beat-
    Dec 17
    		$-0.32$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio4.96EV/EBITDA10.60x
    Price/FCF-15.26xFCF Yield-6.55%
    Profitability
    Profit Margin62.90%Operating Margin39.90%
    ROE72.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio20.30xQuick Ratio20.30x
    Trading Statistics
    Beta-0.33Avg Volume418.46K
    52-Week High$23.5752-Week Low$1.62

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$15.79
    SMA 20$15.76
    SMA 50$14.94
    SMA 200$7.82
    EMA 10$15.64
    EMA 20$15.61
    EMA 50$14.52
    EMA 200$9.28

    MACD

    Line: 0.18Signal: 0.34Hist: -0.15

    ADX

    ADX: 26.4+DI: 19.9-DI: 18.6

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down12.0
    PSAR$16.61

    Bollinger Bands

    Upper Band$16.72
    Lower Band$14.80
    %B Position1216%(Upper)
    Band Width0.03

    RSI (14-Day)

    Neutral
    45.1

    Momentum Oscillators

    Stoch %K26.1
    Stoch %D45.6
    Williams %R-94.6
    ROC (10d)-6.8%
    Momentum-1.08
    CCI (20d)-153.4
    MFI (14d)62.7

    Volatility Measures

    ATR (14d)$1.02(6.9%)
    StdDev (20d)0.48
    Hist Vol49.3%(High)

    Volume Flow

    VWAP$14.98
    OBV259.3M
    AD Line-105.9M
    CMF (20d)-0.021

    Volume Metrics

    Avg Vol (20d)422.9K
    Vol Ratio0.8x
    VWMA (20d)$15.85

    Pivot Points

    R3$17.21
    R2$16.73
    R1$15.88
    Pivot Point$15.40
    S1$14.55
    S2$14.07
    S3$13.22

    Advanced Oscillators

    TSI4.97
    Ultimate Osc42.1
    KST53.58

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$53.74M$0$0$0$0$0$0$0$-14,662,000$1.86M
    Cost of Revenue$0$0$90,000$0$0$0$120,000$0$0$0$124,000$0
    Gross Profit$0$0$53.74M$0$0$0$-120,000$0$0$0$-14,662,000$1.86M
    Operating Expenses$9.12M$7.72M$7.86M$7.58M$9.17M$12.23M$14.53M$18.81M$17.92M$14.84M$11.15M$9.66M
    R&D$4.26M$3.22M$3.32M$3.56M$5.16M$7.12M$10.54M$14.35M$13.41M$9.84M$8.34M$7.46M
    SG&A$4.86M$4.50M$4.54M$4.02M$4.01M$5.10M$3.98M$4.47M$4.51M$5.00M$2.81M$2.19M
    Operating Income$-9,118,000$-7,722,000$45.88M$-7,577,000$-9,171,000$-12,228,000$-14,526,000$-18,814,000$-17,919,000$-14,843,000$-25,809,000$-7,798,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$147,000$0$0$0$0$0$0$0$0$0$1.00M$6.17M
    Income Before Tax$-8,946,000$-7,609,000$57.73M$-7,389,000$-9,489,000$-11,031,000$-14,168,000$-17,595,000$-15,529,000$1.21M$-26,814,000$-13,966,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-8,946,000$-7,609,000$57.73M$-7,389,000$-9,489,000$-11,031,000$-14,189,000$-17,595,000$-16,978,000$1.03M$-27,067,000$-14,031,000
    EBITDA$-8,781,000$-7,486,000$57.86M$-7,252,000$-9,349,000$-10,864,000$-13,999,000$-17,437,000$-15,548,000$1.36M$-26,660,000$-13,835,000
    EBIT$-8,799,000$-7,609,000$57.73M$-7,389,000$-9,489,000$-11,031,000$-14,168,000$-17,595,000$-15,529,000$1.21M$-26,814,000$-13,966,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about QTTB

    News

    Morgan Stanley Initiates Q32 Bio(QTTB.US) With Buy Rating, Announces Target Price $34

    Morgan Stanley has initiated coverage on Q32 Bio (QTTB.US) with a "Buy" rating. The investment bank also set a target price of $34 for the company's stock.

    Moomoo•8/24/26•
    Bullish

    Morgan Stanley initiates Q32 Bio stock at Overweight on drug potential

    Morgan Stanley has initiated coverage on Q32 Bio Inc. (NASDAQ:QTTB) with an Overweight rating and a $34 price target, citing the potential of its drug candidate, bempikibart, for severe alopecia areata. The firm believes the drug could achieve over $1 billion in peak sales and highlighted its potential for differentiation in safety and monitoring burden compared to existing treatments. This positive outlook follows recent news of a proposed public offering and increased price targets from other analysts.

    Investing.com•8/24/26•
    Bullish

    Morgan Stanley initiates Q32 Bio stock at Overweight on drug potential

    Morgan Stanley initiated coverage on Q32 Bio Inc. (NASDAQ:QTTB) with an Overweight rating and a $34.00 price target, citing the potential of its drug bempikibart for severe alopecia areata. The firm expects catalysts within 12-18 months and projects a $1 billion-plus peak sales opportunity. This positive outlook follows Q32 Bio's proposed public offering and positive analyst responses from H.C. Wainwright, Mizuho, and Oppenheimer, all raising their price targets based on promising drug efficacy and safety profiles.

    Investing.com•8/24/26•
    Bullish

    Q32 Bio Sees Unusually Large Options Volume (NASDAQ:QTTB)

    Q32 Bio (NASDAQ:QTTB) experienced an unusually high volume of call options traded, with 7,501 call options changing hands, marking a 790% increase from its typical daily volume. This surge in activity follows significant insider purchases, where Orbimed Advisors and Director Diyong Xu each acquired 1.875 million shares at $8 per share. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $30, even as shares closed at $15.82.

    MarketBeat•8/21/26•
    Bullish

    Q32 Bio Inc. (QTTB) Stock Price | Live Quotes & Charts | NASDAQ

    This NASDAQ page provides live stock quotes and charts for Q32 Bio Inc. (QTTB), showing its current price of $15.12 with a recent decline of 1.63%. It indicates that there are currently no analyst ratings or earnings information available for the company. The page also includes extensive disclaimers about the risks of day trading and general investment.

    Timothy Sykes•8/16/26•
    Neutral

    Frequently Asked Questions About QTTB

    Does QTTB pay dividends?
    Q32 Bio Inc (QTTB) does not currently pay a regular dividend.
    What is QTTB's P/E ratio?
    Q32 Bio Inc has a price-to-earnings (P/E) ratio of 4.96.
    What is QTTB's market cap?
    Q32 Bio Inc (QTTB) has a market capitalization of $447.44M with a current stock price of $14.87.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In